How about the $100M Holy ‘GRAIL’ in Cancer Diagnostics? A Universal Test Start-up Faces German Competition

11/01/2016 - 3 minutes

Illumina, the €22Bn Market cap NGS specialist, and Bill Gates pooled a $100M to fund the startup, ‘Grail’, which will be used to find a universal cancer detection test for Doctors.

illumina_ngs_bill_gates_cancer_diagnostics_liquid_biopsiesThe startup will be based in San Francisco (US) with additional financial backing to include Bill Gates amongst others.  The tests in question are based on the super-sensitive sequencing technology that Illumina had developed for blood tests, able to detect micro-traces of DNA.

And this was around 18 months ago… now the NGS Super Company is projecting costs of such diagnostic tests to be only around $1,000.

The idea for such ‘Liquid Biopsies’ however is not exclusive to Illumina’s network, as another Biotech, Guardant Health, was the first liquid biopsy to be offered to doctors in the United States. The technique was originally discovered and refined at John Hopkins University, the full story of which you can read in MIT’s Technology Review.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member